Expression of Autophagy-Related Proteins in H체rthle Cell Neoplasm Is Different from That in Follicular Neoplasm by 援ъ옄�듅 et al.
Research Article
Expression of Autophagy-Related Proteins in Hürthle Cell
Neoplasm Is Different from That in Follicular Neoplasm
Yoon Jin Cha, Hye Min Kim, and Ja Seung Koo
Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea
Correspondence should be addressed to Ja Seung Koo; kjs1976@yuhs.ac
Received 22 February 2017; Revised 23 June 2017; Accepted 5 July 2017; Published 27 July 2017
Academic Editor: Stamatios E. Theocharis
Copyright © 2017 Yoon Jin Cha et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Purpose.We aimed to evaluate expression of autophagy-related proteins in Hürthle cell neoplasm (HCN) and follicular neoplasm
(FN) and assess the clinical implications.Methods. 265 FNs (112 follicular carcinomas and 153 follicular adenomas) and 108 HCNs
(27 Hürthle cell carcinomas and 81 Hürthle cell adenomas) were made into a tissue microarray. Immunohistochemical staining
and Western blot for autophagy-related proteins (beclin-1, light chain (LC) 3A, LC3B, p62, and BNIP3) were performed, and
the results were statistically analyzed. Results. A higher expression rate of beclin-1, LC3B, p62, and BNIP3 was found in HCN
than in FN (P < 0 001). The expression rate of beclin-1, LC3B, p62, and BNIP3 was the highest in HCCs followed by HCAs, FCs,
and FAs in that order (P < 0 001). HCCs were positive for the largest number of autophagy-related proteins followed by HCAs,
FCs, and FAs (P < 0 001), and most of the positive markers identiﬁed in HCCs were the high autophagy type (P < 0 001),
deﬁned by positive staining for three or more of the ﬁve autophagy-related proteins. Conclusion. The autophagy-related proteins,
beclin-1, LC3A, LC3B, p62, and BNIP3, were more frequently expressed in HCNs than in FNs, and HCCs showed the highest
expression rate.
1. Introduction
Autophagy is the lysosomal disassembly of cellular components
and is separated into microautophagy, chaperone-mediated
autophagy, and macroautophagy subtypes. Macroautophagy
is the major type of autophagy, and its underlying process has
been investigated extensively. Autophagy is the process of
removing and recycling dysfunctional or damaged cellular
components, and it plays an important homeostatic role
[1–4]. Autophagy activity is measured by the expression of
several surrogate proteins involving the autophagy process:
beclin-1 in nucleation [5–8], LC (light chain) 3 in elonga-
tion and generation of the autophagosome [9–11], scaﬀold
protein p62 in transportation of ubiquitinated proteins to
the autophagosome [12, 13], and BNIP3 involving mito-
phagy [14].
Autophagy plays a signiﬁcant role in both tumor and
normal cells. Cancer cells survive via angiogenesis and/or
aerobic glycolysis in harsh environments including hypoxia
and decreased nutrients. Highly aggressive malignant
tumor cells use alternative metabolic pathways to provide
energy via autophagy and to recycle cytoplasmic components
in order to meet high metabolic demands [15, 16]. How-
ever, unrestrained autophagy results in progressive con-
sumption of cellular constituents and subsequent cellular
death [17, 18].
Hürthle cell neoplasm (HCN) of the thyroid is a variant
of follicular neoplasm (FN). Hürthle cell adenoma (HCA)
comprises 10%–15% of follicular adenomas (FA), and
Hürthle cell carcinoma (HCC) accounts for 20%–25% of fol-
licular carcinomas (FC) [19, 20]. Hürthle cells originate from
follicular epithelial cells and are characterized by ample,
granular cytoplasm and prominent nucleoli [21]. In the
current WHO classiﬁcation, HCN is categorized as a variant
of FN [22]. However, there is debate as to whether HCN is a
disease entity distinct from FN owing to its association with
nodal metastasis, higher recurrence rate and disease-related
mortality [23, 24], and frequent TERT C228T promoter
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mutation [25]. As a result, diﬀerent autophagy features are
expected between HCN and FN based on their diﬀering
tumor biology. Autophagy in HCN and FN has not been
evaluated to date. In the present study, we evaluated the
expression of autophagy-related proteins (beclin-1, LC3A,
LC3B, p62, and BNIP3) in HCN and FN and assessed the
clinical implications.
2. Materials and Methods
2.1. Patient Selection. Patients who underwent surgical
resection and were diagnosed with FN and HCN at Severance
Hospital between January 2000 and December 2013 were
included. This study was approved by the Institutional
Review Board of Yonsei University Severance Hospital.
Patients who received preoperative chemotherapy were
excluded. The histology of all resected specimens was retro-
spectively reviewed by a thyroid pathologist (JS Koo) with
hematoxylin and eosin- (H&E-) stained slides. Clinicopath-
ologic data were collected from the medical records and
included age at diagnosis, recurrence, metastasis, death,
follow-up period, tumor size, location (right or left lobe),
tumor extent (intrathyroidal or extrathyroidal), and number
of metastatic lymph nodes.
2.2. Tissue Microarray. Representative areas of hematoxylin-
eosin-stained slides and corresponding spots were marked
on the surface of the matching paraﬃn block. Three-
millimeter cores were taken from selected areas of formalin-
ﬁxed, paraﬃn-embedded tissue (FFPE) and constructed
into a 6× 5 tissue microarray block. More than two tis-
sue cores were extracted from each case, and each tissue
core was assigned a unique tissue microarray location
number that was linked to a database containing clinico-
pathologic data.
2.3. Immunohistochemistry. Antibodies used for immunohis-
tochemistry are listed in Table 1. Sections from the TMA
blocks were used for immunohistochemistry with an auto-
matic immunohistochemistry staining device (Benchmark
XT, Ventana Medical System, Tucson, AZ, USA). Brieﬂy,
5μm thick FFPE sections were transferred onto adhesive
slides and dried at 62°C for 30 minutes. Standard heat epi-
tope retrieval was performed for 30 minutes in ethylene
diamine tetra acetic acid, pH8.0, in the autostainer. The
samples were then incubated with primary antibodies,
followed by biotinylated anti-mouse immunoglobulins,
peroxidase-labeled streptavidin (LSAB kit, DakoCytoma-
tion), and 3,30-diaminobenzidine.
2.4. Interpretation of Immunohistochemical Staining. Immu-
nohistochemical staining was evaluated by light micros-
copy. The stained slides were semiquantitatively evaluated
according to a previously described method [26]. Tumor
cell staining was assessed as 0, negative or weak immuno-
staining in <1% of the tumor/stroma; 1, focal expression
in 1%–10% of the tumor; 2, positive in 11%–50% of the
tumor; and 3, positive in 51%–100% of tumor. The whole
tumor area was evaluated: a score 0-1 was considered neg-
ative and a score 2 or higher was considered positive.
High autophagy status was deﬁned as positive staining
for three or more of the ﬁve autophagy-related proteins.
Tumors were divided into high or low autophagy subtype,
based on the autophagy status.
2.5. Protein Extraction from FFPE Tissues and Western Blot.
Protein extractions from FFPE tissues were performed
using a Qproteome FFPE tissue kit (Qiagen) according
to the manufacturer’s manual. Brieﬂy, two or three sec-
tions from the same block were deparaﬃnized in xylene
and rehydrated in a graded series of ethanol (100%,
96%, and 70%). The tissues were mixed with FFPE
extraction buﬀer containing β-mercaptoethanol, incu-
bated at 100°C for 20min, at 80°C for 2 h with agita-
tion at 750 rpm, and then centrifuged for 15min at
14,000×g at 4°C. Extracted protein content in the super-
natant was determined by Bradford assay (Bio-Rad).
Equal amounts of protein from each sample extract were
separated on SDS-PAGE gels and blotted onto nitrocellu-
lose membranes (Bio-Rad). Western blotting was per-
formed with primary antibodies against beclin-1. LC3A,
LC3B, p62, BNIP3, and GAPDH (Abcam) and speciﬁc
bands were detected using an ECL kit (GE Healthcare
Life Sciences).
2.6. Statistical Analysis. Statistical analyses were performed
using SPSS for Windows, Version 23.0 (SPSS Inc.,
Chicago, IL, USA). Student’s t-test was used for con-
tinuous variables. Chi-square and Fisher’s exact tests
were used for categorical variables. Statistical signiﬁcance
was set at P < 0 05. Kaplan-Meier survival curves and
log-rank statistics were employed to evaluate time to
tumor recurrence and overall survival. Multivariate regres-
sion analysis was performed using the Cox proportional
hazards model.
3. Results
3.1. Baseline Characteristics of Follicular Neoplasms and
Hürthle Cell Neoplasms. There were 265 FNs comprised of
153 FAs and 112 FCs (99 minimally invasive types and 13
widely invasive types), and 108 HCNs comprised of 81 HCAs
and 27 HCCs. Clinicopathologic features of FNs and HCNs
are shown in Supplementary Tables 1 and 2 available online
at https://doi.org/10.1155/2017/1372387, respectively.
3.2. Expression of Autophagy-Related Proteins in Follicular
Neoplasms and Hürthle Cell Neoplasms. Expression of
Table 1: Source, clone, and dilution of antibodies.
Antibody Clone Dilution Company
Beclin-1 Polyclonal 1 : 100 Abcam, Cambridge, UK
LC3A EP1528Y 1 : 100 Abcam, Cambridge, UK
LC3B Polyclonal 1 : 100 Abcam, Cambridge, UK
p62 SQSTM1 1 : 100 Abcam, Cambridge, UK
BNIP3 Ana40 1 : 100 Abcam, Cambridge, UK
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autophagy-related proteins in FNs and HNs is shown in
Figures 1 and 2. Expression of beclin-1, LC3B, p62, and
BNIP3 was signiﬁcantly higher in HCNs than in FNs
(P < 0 001, Table 2). Expression of beclin-1, LC3B, and
BNIP3 was highest in HCCs, followed by HCAs, FCs,
and FAs (P < 0 001, Table 3). HCCs showed the highest
positivity rate for autophagy-related proteins followed by
HCAs, FCs, and FAs (P < 0 001). The frequency of high
autophagy type (positive for three or more autophagy-
related proteins) was highest in HCCs, followed by HCAs,
FCs, and FAs (P < 0 001, Table 4, Figure 3).
Western blot analysis for autophagy-related proteins
in HCC and FC revealed a higher expression of
beclin-1, LC3A, LC3B, and p62 in HCC than in FC
(Figure 4).
3.3. Correlation between the Expression of Autophagy-
Related Proteins and Clinicopathologic Factors in Hürthle
Cell Carcinomas and Follicular Carcinomas. There was
no signiﬁcant association between the expression of
autophagy-related proteins and clinicopathologic factors
in HCCs. In FCs, capsular invasion was associated with
BNIP3 negativity (P = 0 014), low number of positive
markers (P = 0 013), and low autophagy status (P = 0 041),
and larger tumors (>4.0 cm) were associated with high
autophagy status (P = 0 012 and Figure 5).
3.4. The Impact of Autophagy-Related Protein Expression
on Prognosis. Expression of autophagy-related proteins
had no signiﬁcant eﬀect on prognosis of FCs and HCCs
(Table 5).
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Figure 2: Expression of autophagy-related proteins in follicular adenoma, follicular carcinoma, Hürthle cell adenoma (HCA), and Hürthle
cell carcinoma (HCC). Beclin-1, LC3B, p62, and BNIP3 are more highly expressed in Hürthle cell neoplasms than in follicular neoplasms
and in HCCs than in HCAs.
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Figure 1: Heat map showing the expression of autophagy-related proteins in follicular neoplasms and Hürthle cell neoplasms. FA: follicular
adenoma; FC: follicular carcinoma; HCA: Hürthle cell adenoma; HCC: Hürthle cell carcinoma; green: negative; red: positive.
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Table 4: Number of positive autophagy markers in follicular neoplasms and Hürthle cell neoplasms.
Number of positive
markers for autophagy
Total
N = 373 (%)
FA
N = 153 (%)
FC
N = 112 (%)
HCA
N = 81 (%)
HCC
N = 27 (%) P value
0 133 (35.7) 81 (52.9) 49 (43.8) 2 (2.5) 1 (3.7) <0.001
1 131 (35.1) 59 (38.6) 52 (46.4) 19 (23.5) 1 (3.7)
2 43 (11.5) 10 (6.5) 8 (7.1) 22 (27.2) 3 (11.1)
3 49 (13.1) 3 (2.0) 3 (2.7) 31 (38.3) 12 (44.4)
4 17 (4.6) 0 (0.0) 0 (0.0) 7 (8.6) 10 (37.0)
FA: follicular adenoma; FC: follicular carcinoma; HCA: Hürthle cell adenoma; HCC: Hürthle cell carcinoma.
Table 3: Expression of autophagy-related proteins in follicular adenomas, follicular carcinomas, Hürthle cell adenomas, and Hürthle cell
carcinomas.
Parameters
Follicular neoplasm
N = 265 (%)
Hürthle cell neoplasm
N = 108 (%)
P value
FA
N = 153 (%)
FC
N = 112 (%)
HCA
N = 81 (%)
HCC
N = 27 (%)
Beclin-1 <0.001
Negative 153 (100.0) 112 (100.0) 74 (91.4) 18 (66.7)
Positive 0 (0.0) 0 (0.0) 7 (8.6) 9 (33.3)
LC3A 0.411
Negative 141 (92.2) 99 (88.4) 77 (95.1) 25 (92.6)
Positive 12 (7.8) 13 (11.6) 4 (4.9) 2 (7.4)
LC3B <0.001
Negative 153 (100.0) 112 (100.0) 31 (38.1) 2 (7.4)
Positive 0 (0.0) 0 (0.0) 50 (61.7) 25 (92.6)
p62 <0.001
Negative 85 (55.6) 53 (47.3) 2 (2.5) 3 (11.1)
Positive 68 (44.4) 59 (52.7) 79 (97.5) 24 (88.9)
BNIP3 <0.001
Negative 146 (95.4) 107 (95.5) 37 (45.7) 4 (14.8)
Positive 7 (4.6) 5 (4.5) 44 (54.3) 23 (85.2)
FA: follicular adenoma; FC: follicular carcinoma; HCA: Hürthle cell adenoma; HCC: Hürthle cell carcinoma.
Table 2: Expression of autophagy-related proteins in follicular neoplasms and Hürthle cell neoplasms.
Parameters
Total
N = 373 (%)
Follicular neoplasm
N = 265 (%)
Hürthle cell neoplasm
N = 108 (%) P value
Beclin-1 <0.001
Negative 357 (95.7) 265 (100.0) 92 (85.2)
Positive 16 (4.3) 0 (0.0) 16 (14.8)
LC3A 0.218
Negative 342 (91.7) 240 (90.6) 102 (94.4)
Positive 31 (8.3) 25 (9.4) 6 (5.6)
LC3B <0.001
Negative 298 (79.9) 265 (100.0) 33 (30.6)
Positive 75 (20.1) 0 (0.0) 75 (69.4)
p62 <0.001
Negative 143 (38.3) 138 (52.1) 5 (4.6)
Positive 230 (61.7) 127 (47.9) 103 (95.4)
BNIP3 <0.001
Negative 294 (78.8) 253 (95.5) 41 (38.0)
Positive 79 (21.2) 12 (4.5) 67 (62.0)
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4. Discussion
We evaluated the expression of autophagy-related proteins in
FNs and HCNs and observed that every autophagy-related
protein was more highly expressed in HCNs than in
FNs. Hürthle cells have an abnormally large number of
mitochondria, which results in abundant acidophilic,
granular cytoplasm. A previous study showed that XTC.UC1,
a cell line derived from a Hürthle cell tumor, had increased
autophagosome formation, which is consistent with the ﬁnd-
ings of the present study [27]. Biologically, Hürthle cells are
less active than normal follicular epithelial cells [28], and
increased autophagy activity appears to be linked to cellular
functions of the Hürthle cell. Increased autophagy promotes
degradation of ciliary proteins and reduces ciliogenesis [29].
These phenomena have been observed in Hürthle cells
in lymphocytic thyroiditis, Hürthle cell carcinoma, and
Hürthle cell variant papillary thyroid carcinoma [29].
Thus, regardless of the type of thyroid disease, Hürthle
cells have increased autophagy activity, fewer ciliated cells,
and shorter cilia. In this study, FCs and HCCs showed sig-
niﬁcantly higher expression of autophagy-related proteins
compared to FAs and HCAs, which suggests higher autoph-
agy activity in malignant tumors than in their benign
counterparts. Expression of autophagy-related proteins is
reportedly related to malignant progression in various
tumors [30, 31], which is consistent with ﬁndings of the
present study.
BNIP3, which is one of the mitophagy-related proteins,
was more highly expressed in HCNs, as described in a
previous study that showed activation of mitophagy in
Hürthle cells. Mitophagy activation in Hürthle cells has
been found to be ineﬀective [27], and abnormal mitochon-
dria accumulate as a result of reduced turnover due to
defective mitophagy caused by a PARK2 gene mutation.
We also found higher expression of BNIP3 in HCNs, but
mitophagy itself may potentially be defective and further
study is required.
One of the limitations of our study was that we used
immunohistochemistry as an indicator of autophagy activ-
ity, which is a static method that may not be accurate
since autophagy is more likely to be a multistep dynamic
process. Since LC3A and LC3B are components of the
autophagosome, expression of LC3A and LC3B could be
interpreted as increased autophagy activation. However,
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Figure 4: Western blot analysis for expression of autophagy-related
proteins in follicular carcinoma (FC) and Hürthle cell carcinoma
(HCC). Beclin-1, LC3A, LC3B, and p62 are more highly expressed
in HCC than in FC.
0
20
40
60
80
FA FC HCA HCC
Ca
se
 n
um
be
r
0
1
2
3
4
p < 0.001
Number of positive markers
(a)
0
20
40
60
80
100
120
140
160
Ca
se
 n
um
be
r
FA FC HCA HCC
High autophagy type
Low autophagy type
p < 0.001
(b)
Figure 3: Number of positive autophagy-related proteins (a) and autophagy status (b) in follicular adenoma (FA), follicular carcinoma (FC),
Hürthle cell adenoma (HCA), and Hürthle cell carcinoma (HCC). Positivity for various markers and high autophagy type are most frequently
found in HCCs followed by HCAs, FCs, and FAs.
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an increased number of autophagosomes can be derived
from delayed degradation, as well as under situations of
increased autophagy activity. Therefore, monitoring of cel-
lular autophagy ﬂux at diﬀerent time points is the most
accurate for measuring autophagy activity [13]. However,
we used paraﬃn blocks of tumor tissue and could not
evaluate autophagy ﬂux.
The other limitation of the present study is negative
correlation between capsular invasion and expression of
autophagy-related proteins in FC, which were partly incom-
patible with previous study and our conclusion that malig-
nant tumor had higher autophagy activity. In the present
study, HCC had overtly higher autophagy status than HCA
and other FNs. Regarding FN, FC showed higher expression
rate of autophagy-related proteins than FA, but most of
FN encompassing FC and FA belonged to low autophagy
status. Thus, it appears that autophagy-related proteins
might not play an important role in tumor aggressiveness
in FC compared to HCC. As seen in diﬀerent distributions
of recognized somatic mutations between FC and HCC,
tumor aggressiveness like capsular invasion might be more
dependent to factors other than autophagy-related proteins
in FC [21].
Autophagy markers appear to be potential therapeutic
targets in cancer therapy. Autophagy inhibition has been
reported to suppress tumor growth in various tumors
[32–35], and HCCs could be a target for autophagy inhibi-
tion considering its high expression of autophagy markers.
In conclusion, expression of autophagy-related proteins
(beclin-1, LC3B, p62, and BNIP3) was higher in HCNs
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Figure 5: Correlation between the expression of autophagy-related proteins and clinicopathologic factors in follicular carcinoma.
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and HCCs compared to FNs and HCAs, respectively, and
this could have implications in cancer therapeutics.
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